Por: RTTNews Health October 10, 2022
The FDA has declined to approve Supernus Pharmaceuticals Inc.'s () SPN-830, an apomorphine infusion pump, proposed for the continuous treatment of motor fluctuations, i.e., OFF episodes, in Parkinson's disease.In the Complete Response letter, issued today, the FDA has asked the company for additional information and analysis related to the infusion device and drug product across several areas, including labeling, product quality and... + full article
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration approved... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | ABC News
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
ALS drug wins FDA approval despite questionable data | WPLG Local 10
New York Post USA Life September 30, 2022
A much-debated drug for Lou Gehrig’s disease won US approval on Thursday from the Food and Drug Administration. The nod represents a long-desired victory for patients, though it is likely to renew questions about the scientific rigor behind government reviews of... + más
ALS drug gets FDA approval despite uncertainty about effectiveness | ABC7
WPLG Local 10 USA Politics September 30, 2022
WASHINGTON – A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration approved... + más
Associated Press USA Science September 30, 2022
WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.The Food and Drug Administration... + más
The Boston Globe USA Tech September 22, 2022
Engineers at the Massachusetts Institute of Technology recently unveiled a radar-like device that could test people for signs of Parkinson’s disease as they slept. Now, they say the same system can monitor Parkinson’s patients in a different way, by tracking how they... + más
Alzheimer's Q&A: Yoga, massage and more could reduce Parkinson's effects | The Advocate
Gerotechnology zeroes in on dementia-related products: Alzheimer's Q&A | The Advocate
The Advocate USA Health September 17, 2022
What are some integrative therapies to consider in Parkinson’s disease?Parkinson’s disease is a neurodegenerative disorder that affects the predominantly dopamine-producing neurons in a specific area of the brain called substantia nigra. Parkinson’s dementia, causing a... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Alzheimer's Q&A: Bright light therapy has multiple benefits | The Advocate
About iurex | Privacy Policy | Disclaimer |